Journal of Health & Wellness

Volume of semen as a parameter of its quality

Metabolic crossroads of iron and copper

This review argues that iron and copper metabolism are tightly interconnected rather than separate nutrient systems. Collins’ central point is that copper status can directly shape iron absorption, transport, and utilization, which helps explain why copper deficiency often produces anemia and other signs that resemble iron deficiency. The paper is explicitly framed as a review of “recent data on copper-iron interactions,” with emphasis on intestinal absorption and systemic iron handling. A major theme in the paper is that copper-dependent proteins are required for normal iron movement through the body. The review highlights ferroxidase enzymes such as hephaestin and ceruloplasmin, which help oxidize iron into a form that can be loaded onto transferrin and transported effectively. The article links impaired activity of these proteins to disrupted iron export and abnormal tissue iron distribution. The intestine is presented as one of the key “crossroads” between the two metals. The review discusses how copper deficiency can reduce intestinal hephaestin activity, which in turn impairs iron absorption and contributes to systemic iron deficiency. It also points to the role of copper transport machinery, including ATP7A, in maintaining the copper supply needed for these iron-related processes. Another important point is that the relationship is not simply theoretical or biochemical. The paper ties the iron-copper connection to classic animal findings showing that copper deficiency can cause anemia that does not fully respond to iron alone. That observation supports the review’s broader conclusion that some anemia states reflect a failure of iron utilization or trafficking caused by inadequate copper-dependent metabolism, not just a lack of iron intake. Overall, the paper’s message is that copper is essential to normal iron homeostasis at multiple levels: intestinal uptake, iron export from cells, plasma transport, and tissue delivery. The review presents copper deficiency as a clinically meaningful cause of disturbed iron metabolism and positions the two trace minerals as metabolically interdependent.

Copper-2 Ingestion, Plus Increased Meat Eating Leading to Increased Copper Absorption, Are Major Factors Behind the Current Epidemic of Alzheimer’s Disease

This paper is not a neutral overview of Alzheimer’s disease; it is a hypothesis-driven review/opinion article arguing that a specific form of copper exposure is a major cause of the modern Alzheimer’s epidemic. Brewer’s central claim is that divalent inorganic copper (“copper-2”) from drinking water carried through copper plumbing and from copper-containing supplement pills, along with greater meat consumption that may increase copper absorption, are major contributors to Alzheimer’s disease in developed countries. The article’s argument rests on several lines of reasoning rather than a single definitive experiment. It points to animal studies in which small amounts of inorganic copper in drinking water reportedly worsened Alzheimer-like pathology and memory loss, and it cites human observational work suggesting faster cognitive decline among people taking copper-containing supplement pills in the setting of a high-fat diet. The paper also argues that developed-country trends in copper plumbing and meat consumption parallel the rise in Alzheimer’s disease. A key distinction in the paper is between inorganic copper-2 and copper obtained naturally in food. Brewer argues that food copper is handled differently biologically, while copper-2 from water and supplements may bypass normal liver handling to a greater extent and therefore be more neurotoxic. On that basis, the paper presents environmental copper exposure as a plausible driver of disease rather than just a coincidental association. The most important caveat is that this paper presents a strong causal thesis, not established medical consensus. Later commentary specifically challenged the “Copper-2 Hypothesis,” noting that Switzerland has much lower copper exposure from plumbing and lower intake of some of the proposed risk factors, yet a similar Alzheimer’s incidence to the United States. That commentary argued this contradicts the hypothesis. Another later paper by Brewer continued to promote the same idea, showing the topic remained debated rather than settled. Overall, the paper’s summary is: Brewer argues that modern exposure to inorganic copper-2, especially from plumbing and supplements, plus dietary patterns that increase copper absorption, may be major environmental causes of Alzheimer’s disease in developed countries. But this should be read as a controversial hypothesis review, not proof that copper exposure has been established as a major cause of Alzheimer’s.

Copper in Drinking Water

Copper in drinking water usually comes not from the original water source, but from household plumbing. The Minnesota Department of Health says copper can leach into water as it moves through copper pipes, fittings, or other plumbing components, especially when water sits in the pipes for long periods or when the plumbing is relatively new and has not yet developed a protective mineral coating. The page explains that copper is an essential nutrient in small amounts, but too much can be harmful. High copper exposure from drinking water may cause headaches, nausea, vomiting, diarrhea, stomach cramps, liver damage, kidney disease, and red blood cell problems. It also notes that infants under one year old and people with Wilson’s disease are more sensitive because their bodies do not remove excess copper as effectively. Minnesota’s guidance says drinking water with more than 1,300 micrograms of copper per liter can present a health risk. To reduce exposure, the state recommends letting the water run for 30 to 60 seconds before using it for drinking or cooking if it has been sitting in the pipes for more than six hours, and using only cold water for drinking, cooking, and making infant formula because hot water can dissolve more copper from plumbing. The department also recommends testing tap water if there is ongoing concern, especially if an infant or someone with Wilson’s disease may drink it. If testing still shows copper above 1,300 µg/L after flushing the tap, the page says homeowners may want to consider home water treatment. For private well users, the page notes that copper usually does not come from the groundwater itself, but from plumbing materials in the home. For people on public water systems, the page explains that the U.S. EPA uses an action level of 1,300 µg/L. Public water systems must act if more than 10% of tested homes and sampling sites exceed that level. However, the page cautions that a home’s own plumbing may still produce higher copper levels at the tap than what appears in the community system’s general water quality report. The page also notes that signs of corrosive water can include pinhole leaks, pitting in pipes, blue-green staining on fixtures, or water that tastes bad, smells unusual, or appears blue. It adds that if corrosive water is present, lead may also be a concern. The Minnesota Department of Health last updated the page on September 25, 2024.

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

The paper "Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options" is a broad review of medication treatment for adult anxiety disorders, focused on panic disorder, generalized anxiety disorder, social anxiety disorder, and specific phobias. It does not cover PTSD or OCD. Its two main goals are to summarize currently used medications, including both approved and off-label options, and to assess newer drug classes being investigated. The review’s core conclusion is that SSRIs and SNRIs remain the main first-line medication treatments for panic disorder, generalized anxiety disorder, and social anxiety disorder. The authors describe them as effective and generally well tolerated, while noting familiar drawbacks such as nausea, headache, GI side effects, and especially sexual dysfunction. They also note that older antidepressants such as tricyclics and MAOIs can work, but are used less often because of side-effect burden, overdose risk, and dietary restrictions. Beyond SSRIs and SNRIs, the paper reviews a wide range of commonly used alternatives and adjuncts. These include buspirone, which is FDA-approved for anxiety and used especially in GAD; benzodiazepines, which remain effective but are no longer favored as first-line monotherapy because of concerns about dependence, misuse, falls, and prescribing patterns; and other off-label options such as mirtazapine, hydroxyzine, propranolol, clonidine, pregabalin, gabapentin, and some antipsychotics. The review presents these as part of real-world anxiety pharmacotherapy, but not as clear replacements for first-line serotonergic agents. A major theme of the article is that the pipeline for new anxiety medications has been relatively weak. The authors say there have been few drugs developed specifically for anxiety disorders, and that many newer studies suffer from poor design, including limited controls and too few head-to-head comparisons against established treatments like SSRIs or benzodiazepines. They also note a broader problem: despite multiple available treatments, a substantial minority of patients still have treatment-refractory anxiety. For emerging therapies, the review discusses investigational approaches involving glutamate modulators, neuropeptides, neurosteroids, cannabinoids, and natural remedies. However, its overall assessment is cautious: randomized controlled evidence is limited, and many recent trials have been negative. The review specifically says that while some recent studies of agents such as ketamine, d-cycloserine, and cannabidiol have been conducted, results have mostly been disappointing, with only kava and PH94B, an inhaled neuroactive steroid, standing out as showing some promise. Overall, the paper argues that current anxiety pharmacotherapy still depends heavily on established medication classes, especially SSRIs and SNRIs, while genuinely novel options remain underdeveloped. The authors’ bottom line is not that there are no promising new directions, but that the field needs larger, better-designed studies and more research into new biological pathways before emerging treatments can meaningfully change practice.

IS SEMINAL VESICULITIS A DISCRETE DISEASE ENTITY?

A 2004 study published in The Journal of Urology explored whether seminal vesiculitis should be considered a separate disease entity in men with acute epididymitis. The researchers focused on 13 patients clinically diagnosed with acute epididymitis and evaluated the seminal vesicles using imaging, cytology, and bacteriological analysis. The study found that 12 of the 13 patients, or 92.3%, had dilation of the seminal vesicle on the same side as the epididymitis when examined by transrectal ultrasonography. By comparison, dilation on the opposite side was seen in only four patients. Fluid collected from the seminal vesicle on the affected side showed inflammatory findings in all patients studied. Among patients age 40 and younger, Chlamydia trachomatis was detected in seminal vesicle fluid in seven of eight cases where first-void urine testing was also positive for the organism. Based on these findings, the authors concluded that inflammatory involvement of the seminal vesicles is clearly associated with acute epididymitis and that seminal vesiculitis may represent a discrete clinical entity rather than simply a secondary or incidental finding. The paper is titled “Is seminal vesiculitis a discrete disease entity? Clinical and microbiological study of seminal vesiculitis in patients with acute epididymitis” and was published in April 2004.